Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Belatacept (Primary) ; Efalizumab (Primary)
- Indications Islet cell transplant rejection
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 03 Sep 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2017 as reported by ClinicalTrials.gov.